Maria Lopes, MD, MS

Ayman Al-Hendy, MD, PhD and Maria Lopes, MD, MS discuss common concerns that women seek care for during their reproductive years, including uterine fibroids, endometriosis, and unintended pregnancy.

Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.

Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.

Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.

Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.

Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.

Closing out their discussion on glaucoma management, experts share practical advice for care providers and payers alike.

Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.

Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years.

Expert panelists review the use of MIGS and other channel procedures in patients with glaucoma.

Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.

A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.

A review of selective laser trabeculoplasty in glaucoma management, and when it is appropriate to consider as a treatment option.

A review of the novel sustained release approach with bimatoprost implants and how this is affecting glaucoma management.

Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.

A comprehensive review of the therapeutic classes available for patients with prostate cancer.

Panelists discuss the role of rho kinase inhibitors in glaucoma management respective to cost, efficacy, and ease of use.

Shared insight on the importance of patient adherence in glaucoma management, and how this is influenced by therapeutic regimens.

Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.

A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.

Expert perspectives on the factors that inform therapy selection when managing patients with glaucoma.

Experts debate the use of generic agents over branded therapy when managing patients with glaucoma.

A broad review of therapeutic classes approved for the management of glaucoma and how they may be sequenced.

Following a brief discussion on utilization management, experts discuss the current paradigm of patient access to therapy.

Experts highlight early detection and the goals of therapy when managing patients with glaucoma.

A brief overview of vision preservation in glaucoma and the importance of preventing peripheral vision loss and patient falls.

Panelists discuss the worldwide gaps in diagnosis of glaucoma and how this negatively affects patient outcomes.

Shared insight on factors that put patients at risk for glaucoma and how screening can improve early diagnosis and care.

Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.